Allogene Therapeutics Inc (ALLO)

NASDAQ
Currency in USD
Disclaimer
3.17
-0.24(-7.04%)
Closed
After Hours
3.18+0.01(+0.32%)
Trading near 52-week Low
Day's Range
3.083.47
52 wk Range
3.0812.21
Prev. Close
3.41
Open
3.44
Day's Range
3.08-3.47
52 wk Range
3.08-12.21
Volume
2,859,080
Average Volume (3m)
1,903,992
1-Year Change
-70.17%
Shares Outstanding
167,626,365
Analysts
Technical
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
16.86
Upside +431.86%

People Also Watch

8.36
TGTX
-4.67%
55.93
AAP
+1.56%
28.75
TPR
+2.08%
7.10
SRRK
-2.61%
4.220
AMRX
-2.54%

Allogene Therapeutics Inc Company Profile

Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer. It is engaged in developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced T cell manufacturing technologies. Its advanced product candidates, ALLO-501 and ALLO-501A, are engineered allogeneic CAR T cell therapies that target CD19, a protein expressed on the cell surface of B cells and a validated target for B cell-driven hematological malignancies. It is also developing engineered allogeneic CAR T cell product candidates for multiple myeloma, clear cell renal cell carcinoma (ccRCC), and other blood cancers and solid tumors. Its lead product candidates include ALLO-501, ALLO-501A, ALLO-715, ALLO-605, ALLO-316, and ALLO-647.

Income Statement